PDL BioPharma - Edison Group

Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

Pharnext

MCap

1m

Last close

EUR0.10

▲ 0.03 (42.86%)

MoneyHero

MCap

USD60m

Last close

USD2.35

▲ 0.55 (30.56%)

MGI – Media and Games Invest

MCap

EUR235m

Last close

EUR1.50

▲ 0.35 (30.21%)
Sectors
Sectors
Investment Strategy
Investment Strategy
View All

Latest
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

James Brotherton Financial Director — Tyman
Equity Research
Investor Relations
Contact us

Overview
Financials
Research
Thematics

Edison Investment Research is terminating coverage on PDL BioPharma. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare |
Update

17.11.20

PDL BioPharma — Dissolution set for the year end

Healthcare |
Update

25.08.20

PDL BioPharma — Selling off Noden

Healthcare |
Update

27.05.20

PDL BioPharma — Evofem shares distributed and Phexxi approved

Healthcare |
Update

30.03.20

PDL BioPharma — Accelerating asset monetization

Sector

Healthcare

Financials

Edison Investment Research is terminating coverage on PDL BioPharma. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Update

Healthcare

13.11.18

PDL BioPharma — Q318 results

Update

Healthcare

16.08.18

PDL BioPharma — Big in Japan

Update

Healthcare

22.05.18

PDL BioPharma — First quarter results

Update

Healthcare

21.03.18

PDL BioPharma — A strong year

Update

Healthcare

20.11.17

PDL BioPharma — Seeking additional commercial products

Update

Healthcare

10.05.17

PDL BioPharma — Q1 earnings

Outlook

Healthcare

28.03.17

PDL BioPharma — Building the Noden platform

Update

Healthcare

08.12.16

PDL BioPharma — Update 8 December 2016

Update

Healthcare

11.08.16

PDL BioPharma — Update 11 August 2016

Update

Healthcare

15.07.16

PDL BioPharma — Update 15 July 2016

Update

Healthcare

02.06.16

PDL BioPharma — Update 2 June 2016

Update

Healthcare

12.05.16

PDL BioPharma — Update 12 May 2016

Update

Healthcare

04.03.16

PDL BioPharma — Update 3 March 2016

Update

Healthcare

18.11.15

PDL BioPharma — Update 17 November 2015